跳至主要内容
临床试验/CTRI/2024/11/077144
CTRI/2024/11/077144尚未招募2 期

Comparative Evaluation of Effectiveness of Moringa Oliefera Capsules and Lycopene Capsules in the Management of Oral Submucous Fibrosis – A Randomized Controlled Trial.

Dr M Kavinraj1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年11月25日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
50
试验地点
1
主要终点
Evaluation of the following Parameters

研究概览

简要总结

Oral submucous fibrosis, till date having no definite treatment has been treated with various treatment modalities, which includes the use of various antioxidant and anti-inflammatory therapies. Of all the antioxidants tried in OSMF, lycopene has shown to be an effective antioxidant. There is high reactivity between the long polyene chain and free radicals which enables the elimination of singlet oxygen and the reduction of reactive oxygen species (ROS). But long term use of lycopene may cause lycopenemia, which manifests as deposition of lycopene in liver and orange discolouration of skin. Therefore, newer modalities are needed to  be tried in chronic inflammatory conditions like OSMF. Moringa oliefera is a mineral and vitamin rich nutritious and medicinally important tree species. Moringa leaves also has potent antioxidant activity, due to phenolic compounds and flavonoids in it. Oral submucous fibrosis, till date having no definite treatment has been treated with various treatment modalities, which includes the use of various antioxidant and anti-inflammatory therapies. Considering these properties, Moringa oliefera can be considered in the management of OSMF. Also comparing it with lycopene, an effective antioxidant, would further help in better understanding its potential in the management of OSMF.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant and Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • 1.Patients in INTERINCISAL OPENING RANGE of 15-35mm.
  • oral sub mucous fibrosis grade1,2,3 acc.to Khanna and Andrade classification (1995).
  • 2.No history of prior treatment for the same.
  • 3.Patient willing for habit cessation and visit the hospital for regular follow up.

排除标准

  • 1.Patients with systemic disease.
  • 2.Patients with trismus due to other reason (pericoronitis, abscess).
  • 3.Presence of other premalignant lesion (leukoplakia, oral lichen planus) or malignancy.
  • 4.History of hypersensitivity to moringa oliefera and its components.
  • 5.Any tongue abnormalities and disorders.
  • 6.Missing upper and lower central incisors 7.Pregnant and lactating mothers.

结局指标

主要结局

Evaluation of the following Parameters

时间窗: Patients will be recalled at the end of 1st week ,2nd week ,4th week, at the end of 2nd month and 3rd month. Post treatment follow up will be done on monthly basis for three months.

1.Maximal interincisal opening using Vernier Caliper.

时间窗: Patients will be recalled at the end of 1st week ,2nd week ,4th week, at the end of 2nd month and 3rd month. Post treatment follow up will be done on monthly basis for three months.

2.Reduction of burning sensation on the VAS scale

时间窗: Patients will be recalled at the end of 1st week ,2nd week ,4th week, at the end of 2nd month and 3rd month. Post treatment follow up will be done on monthly basis for three months.

3.Increase in tongue protrusion measured by using steel scale.

时间窗: Patients will be recalled at the end of 1st week ,2nd week ,4th week, at the end of 2nd month and 3rd month. Post treatment follow up will be done on monthly basis for three months.

4.Cheek flexibility.

时间窗: Patients will be recalled at the end of 1st week ,2nd week ,4th week, at the end of 2nd month and 3rd month. Post treatment follow up will be done on monthly basis for three months.

次要结局

  • side effects of intervention if any(Patient will be recalled at the end of 1st week,)

研究者

发起方
Dr M Kavinraj
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr M Kavinraj

Government Dental College and Hospital Nagpur

研究点 (1)

Loading locations...

相似试验